Last reviewed · How we verify
Fludara
At a glance
| Generic name | Fludara |
|---|---|
| Also known as | fludarabine, Fludarabine |
| Sponsor | Celyad Oncology SA |
| Target | Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acute myeloid leukemia, disease
- Chronic lymphoid leukemia, disease
- Low-grade B cell non-Hodgkin lymphoma
- Mantle cell lymphoma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Pneumonia
- Fever and chills
- Infection
- Nausea and vomiting
- Malaise
- Fatigue
- Anorexia
- Weakness
- Edema
Serious adverse events
- Autoimmune hemolytic anemia
- Tumor lysis syndrome
- Pancytopenia
- Bone marrow fibrosis
- Pulmonary toxicity/ARDS
- Pulmonary hemorrhage
- Pulmonary fibrosis
- Respiratory failure
- Hemorrhagic cystitis
- Pericardial effusion
Key clinical trials
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (PHASE2, PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers (PHASE1, PHASE2)
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fludara CI brief — competitive landscape report
- Fludara updates RSS · CI watch RSS
- Celyad Oncology SA portfolio CI